Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-21-065716
Date:2021-11-19
Issuer: FLEXION THERAPEUTICS INC (FLXN)
Original Submission Date:

Reporting Person:

COLELLA SAMUEL D
C/O FLEXION THERAPEUTICS, INC.
10 MALL ROAD, SUITE 301 BURLINGTON, MA 01803

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2021-11-19 D 9,000 d $8.50 0 direct
COMMON STOCK 2021-11-19 D 1,000 d $8.50 0 indirect
COMMON STOCK 2021-11-19 D 72,035 d $8.50 0 indirect
COMMON STOCK 2021-11-19 D 5,000 d $8.50 0 indirect
COMMON STOCK 2021-11-19 D 994,129 d $8.50 0 indirect
COMMON STOCK 2021-11-19 D 5,871 d $8.50 0 indirect
COMMON STOCK 2021-11-19 D 388,683 d $8.50 0 indirect
COMMON STOCK 2021-11-19 D 943 d $8.50 0 indirect
COMMON STOCK 2021-11-19 D 19,653 d $8.50 0 indirect
COMMON STOCK 2021-11-19 D 250 d $8.50 0 indirect
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION (RIGHT TO BUY) 17.61 2021-11-19 deemed execution date D 9,000 (d) 2024-03-02 common stock 9,000 $17.61 0 direct
STOCK OPTION (RIGHT TO BUY) 21.85 2021-11-19 deemed execution date D 9,000 (d) 2025-06-16 common stock 9,000 $21.85 0 direct
STOCK OPTION (RIGHT TO BUY) 13.83 2021-11-19 deemed execution date D 12,500 (d) 2026-06-09 common stock 12,500 $13.83 0 direct
STOCK OPTION (RIGHT TO BUY) 20.16 2021-11-19 deemed execution date D 12,500 (d) 2027-06-21 common stock 12,500 $20.16 0 direct
STOCK OPTION (RIGHT TO BUY) 28.14 2021-11-19 deemed execution date D 12,500 (d) 2028-06-19 common stock 12,500 $28.14 0 direct
STOCK OPTION (RIGHT TO BUY) 11.74 2021-11-19 deemed execution date D 12,500 (d) 2029-06-18 common stock 12,500 $11.74 0 direct
STOCK OPTION (RIGHT TO BUY) 11.88 2021-11-19 deemed execution date D 7,000 (d) 2030-06-09 common stock 7,000 $11.88 0 direct
STOCK OPTION (RIGHT TO BUY) 9.22 2021-11-19 deemed execution date D 7,000 (d) 2031-06-23 common stock 7,000 $9.22 0 direct
Footnotes
IDfootnote
f1 pursuant to the agreement and plan of merger, dated as of october 11, 2021, by and among flexion therapeutics, inc. ("issuer"), pacira biosciences, inc. and oyster acquisition company inc. ("purchaser") ("merger agreement"), on november 19, 2021, purchaser merged with and into issuer, with issuer continuing as the surviving corporation ("merger"). at the effective time of the merger, each share of issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("cash amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to december 31, 2030 ("cvr payments"). pursuant to the merger agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the cash amount, plus (ii) any cvr payments.
f2 at the effective time of the merger, each outstanding restricted stock unit award ("rsu") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of issuer common stock issuable in settlement of such rsu in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential cvr payments.
f3 2,198 shares were inadvertently reported as held directly by the reporting person. the shares are held by the colella family trust uta dtd 9/21/92.
f4 the shares are held by the colella family trust uta dtd. 9/21/92 ("colella trust"). the reporting person is a trustee and beneficiary of the colella trust.
f5 the shares are held by the colella family exempt marital deduction trust dated 9/21/1992 ("colella exempt trust"). the reporting person is a trustee and beneficiary of the colella exempt trust.
f6 the shares are held by versant venture capital iii, l.p. ("vvc iii"). the reporting person is a managing member of versant ventures iii, llc ("vv iii"), the sole general partner of vvc iii and shares voting and dispositive power over the shares held by vvc iii; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein.
f7 the shares are held by versant side fund iii, l.p. ("side fund iii"). the reporting person is a managing member of vv iii, the sole general partner of side fund iii and shares voting and dispositive power over the shares held by side fund iii; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein.
f8 the shares are held by versant development fund iii, llc ("development iii"). the reporting person is a managing member of vv iii, a majority member of development iii and shares voting and dispositive power over the shares held by development iii; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein.
f9 shares held by colella partners. the reporting person is the general partner of colella partners.
f10 shares held by colella partners ii. the reporting person is the general partner of colella partners ii.
f11 at the effective time of the merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential cvr payments) in respect of such cancelled option.
WhaleWisdom Logo

Elevate your investments